RNA-Triggered CRISPR System Selectively Kills Cancer and Viral Cells by Shredding Their DNA, Researchers Report in Nature

Overview

Researchers have unveiled a novel CRISPR-based system that does not edit genes but instead destroys targeted diseased cells by shredding their DNA. The technology, built around the nuclease Cas12a2, recognizes specific RNA transcripts and, upon binding, triggers indiscriminate DNA cleavage that overwhelms the cell and causes it to self-destruct. Unlike conventional CRISPR-Cas9, which makes precise cuts for editing, Cas12a2 acts like a molecular paper shredder once activated.

The findings, published May 6, 2026 in Nature under the title “RNA-triggered cell killing with CRISPR–Cas12a2,” were led by teams at the University of Utah, Utah State University, Akribion Therapeutics, and the Helmholtz Institute for RNA-based Infection Research (HIRI) University of Utah Health. The work demonstrates selective killing of cancer cells carrying a common KRAS mutation and of cells infected with human papillomavirus (HPV), with initial mouse model validation.

What We Know

Cas12a2 is a type V CRISPR nuclease previously shown in 2023 bacterial studies to recognize RNA targets and then indiscriminately cleave double-stranded DNA, single-stranded DNA, and RNA. In the new eukaryotic work, the team programmed the system with guide RNAs to detect disease-specific transcripts. Once the target RNA is recognized, Cas12a2 activates and “shreds all DNA it encounters, effectively killing the cell,” according to co-corresponding author Ryan Jackson of Utah State University Helmholtz Centre for Infection Research.

In human lung cancer cells harboring the oncogenic KRAS G12C mutation, Cas12a2 treatment reduced cell growth by approximately 50 percent in culture—comparable in effect to the chemotherapy drug cisplatin—while having no measurable impact on cells with wild-type KRAS University of Utah Health. Co-senior author Yang Liu of the University of Utah emphasized the specificity: “The enzyme that we’re working with is extremely specific. It does not touch the healthy cells. So if we’re thinking about a cancer therapy, you’re treating cancer with no side effects. That was striking to us. We did not know that was possible.”

For viral applications, the system was directed against HPV E6/E7 transcripts. In cell culture, it reduced growth of infected cells by more than 90 percent without harming uninfected cells. In mouse models, direct injection into HPV-infected tumors slowed tumor growth University of Utah Health. Paul Scholz, co-founder and head of R&D at Akribion Therapeutics and a corresponding author, stated: “Our technology provides us with a powerful tool for sequence-specific depletion of pathogenic cells.” The company is advancing the platform, referred to as G-dase-E, with a lead program in HPV-positive head and neck cancer targeting in vivo proof-of-concept data and preclinical development candidate nomination in 2026 Helmholtz Centre for Infection Research.

Additional demonstrations showed the nuclease could enrich for successful gene-edited cells by eliminating unedited or unsuccessfully edited ones, achieving 3- to 4-fold improvements in some assays. Cell death was sequence-specific, highly sensitive to guide RNA mismatches, and occurred without detectable off-target activation in the tested systems.

The international collaboration includes researchers from the University of Utah Health, Huntsman Cancer Institute, Utah State University, Akribion Therapeutics (a BRAIN Biotech spin-off), BRAIN Biotech AG, the Helmholtz Institute for RNA-based Infection Research, and the University of Würzburg. Key quotes from co-first author Jared Thompson of the University of Utah highlight the long-standing biomedical challenge: “For as long as medicine has been practiced, a significant challenge has been: how do we eliminate harmful cells without damaging healthy ones?” @theU .

What We Don’t Know

The large majority of experiments were conducted in cells in a dish and limited mouse tumor models. Full in vivo studies addressing biodistribution, delivery efficiency, immunogenicity, long-term safety, and efficacy in whole organisms are still needed before the approach can advance to human clinical trials. Researchers caution that different organ systems may take up Cas12a2 differently and that the effects of the protein itself—even when not activated—remain to be fully characterized in living systems University of Utah Health.

Delivery of sufficient quantities of the nuclease (as RNPs, via electroporation, or lipid nanoparticles) to the relevant tissues also presents a fundamental technical hurdle. While the team plans further development toward clinical applications, no timeline for first-in-human testing has been disclosed.

Analysis

This work significantly expands the CRISPR toolkit beyond precision gene editing into programmable, transcript-specific cell elimination. By turning an RNA biomarker into a self-destruct signal, Cas12a2 offers a potential route to therapies that spare healthy tissue far more effectively than traditional chemotherapy or less selective approaches. The commercial interest from Akribion Therapeutics, combined with the ongoing American Society of Gene & Cell Therapy (ASGCT) 2026 meeting in Boston (May 11–15), underscores growing momentum for in vivo and non-editing gene and cell therapies.

If delivery and safety challenges can be overcome, the technology could find uses not only in oncology and virology but also in clearing senescent cells for age-related conditions or selectively removing malfunctioning cells in neurodegenerative diseases. The proof-of-principle already achieved in cancer mutations and viral transcripts, paired with the enrichment capability for gene editing workflows, positions Cas12a2 as a versatile new molecular scalpel for both research and potential medicine.

The paper is open-access in Nature (DOI: 10.1038/s41586-026-10466-y). Researchers expressed optimism that the broader community will now explore and refine the platform, with one senior author noting the goal of “curing the incurables.”